Researchers find wide variation among individual endoscopists and centers in adherence to established quality indicators in Barrett esophagus and suggest targets for improvement.
The oral potassium-competitive acid blocker vonoprazan was noninferior and superior to the proton pump inhibitor lansoprazole for erosive esophagitis in a phase 3 trial.
With a lower price tag and fewer complications than sedated endoscopy, experts said the transnasal approach could help primary care physicians catch potential GI cancers early.